SCHEMBL3388145

SCHEMBL3388145

Cc1nc(N(C)c2ccco2)c2c(-c3ccccc3)csc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.45
LMNA P02545 7/20 0.44
KMT2A Q03164 4/20 0.44
MAPT P10636 5/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAPK1 P28482 3/20 0.39
TSHR P16473 1/20 0.39
KDM4E B2RXH2 4/20 0.38
MEN1 O00255 2/20 0.38
RAB9A P51151 3/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NPC1 O15118 2/20 0.36
HTT P42858 2/20 0.36
DAPK3 O43293 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
ABL1 P00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368309 0.82 LMNA (0.55) ALDH1A1LMNAKMT2ASMN1; SMN2MAPK1
SCHEMBL379746 0.76 KDR (0.39) ALDH1A1LMNAKMT2AMAPK1TSHR
SCHEMBL2369096 0.76 ALDH1A1 (0.47) ALDH1A1LMNAKMT2AMAPTGAA
SCHEMBL16294172 0.75 ALDH1A1 (0.56) ALDH1A1LMNAMAPTGAASMN1; SMN2
SCHEMBL2368859 0.71 HTT (0.43) ALDH1A1LMNAKMT2AMAPTTDP1
SCHEMBL2368765 0.71 ALDH1A1 (0.60) ALDH1A1LMNAKMT2AMAPTGAA
SCHEMBL3388141 0.70 ALDH1A1 (0.57) ALDH1A1LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL379641 0.70 KDR (0.43) ALDH1A1MAPTGAASMN1; SMN2ALOX15
SCHEMBL2368979 0.67 LMNA (0.36) ALDH1A1LMNAKMT2AMAPTGAA
SCHEMBL3382534 0.67 HTT (0.48) ALDH1A1LMNAKMT2AMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 ALDH1A1 247/4885LMNA 1126/4885KMT2A 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.